Browsing by Author "Nanda, Japbani K."

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    Incidence of New Primary Cutaneous Melanoma in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors A Single-Center Cohort Study
    (2021) Nanda, Japbani K.; Dusza, Stephen W.; Navarrete-Dechent, Cristian; Liopyris, Konstantinos; Marghoob, Ashfaq A.; Marchetti, Michael A.
    Question What is the incidence of new primary cutaneous melanoma (CM) after initiating immune checkpoint inhibitor therapy for metastatic melanoma? Findings In this single-center observational cohort study, 42 of 2251 patients (1.9%) who received immune checkpoint inhibitors were diagnosed with 48 melanomas. The incidence rate was approximately 1100 cases per 100000 person-years, and the cumulative cause-specific risk of new CM after 5 years was 4.9%; patients diagnosed with a new primary CM were more likely to have a family history of melanoma. Meaning Patients who receive checkpoint inhibitors for treatment of metastatic melanoma remain at risk for the development of new primary CMs.